JP5734180B2 - Ｉｇｆ−ｉｉ／ｉｇｆ−ｉｉｅ結合タンパク質 - Google Patents

Ｉｇｆ−ｉｉ／ｉｇｆ−ｉｉｅ結合タンパク質 Download PDF

Info

Publication number
JP5734180B2
JP5734180B2 JP2011508703A JP2011508703A JP5734180B2 JP 5734180 B2 JP5734180 B2 JP 5734180B2 JP 2011508703 A JP2011508703 A JP 2011508703A JP 2011508703 A JP2011508703 A JP 2011508703A JP 5734180 B2 JP5734180 B2 JP 5734180B2
Authority
JP
Japan
Prior art keywords
igf
iie
growth hormone
antibody
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011508703A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011523405A5 (OSRAM
JP2011523405A (ja
Inventor
ダニエル ドランスフィールド，
ダニエル ドランスフィールド，
エドワード コーエン，
エドワード コーエン，
ティモシー アダムス，
ティモシー アダムス，
リアー コスグローブ，
リアー コスグローブ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Commonwealth Scientific and Industrial Research Organization CSIRO
Original Assignee
Commonwealth Scientific and Industrial Research Organization CSIRO
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commonwealth Scientific and Industrial Research Organization CSIRO filed Critical Commonwealth Scientific and Industrial Research Organization CSIRO
Publication of JP2011523405A publication Critical patent/JP2011523405A/ja
Publication of JP2011523405A5 publication Critical patent/JP2011523405A5/ja
Application granted granted Critical
Publication of JP5734180B2 publication Critical patent/JP5734180B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2011508703A 2008-05-09 2009-05-08 Ｉｇｆ−ｉｉ／ｉｇｆ−ｉｉｅ結合タンパク質 Expired - Fee Related JP5734180B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US5195608P 2008-05-09 2008-05-09
US61/051,956 2008-05-09
US5342708P 2008-05-15 2008-05-15
US61/053,427 2008-05-15
US16318009P 2009-03-25 2009-03-25
US61/163,180 2009-03-25
PCT/US2009/043273 WO2009137758A2 (en) 2008-05-09 2009-05-08 Igf-ii/gf-iie binding proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014016462A Division JP2014077020A (ja) 2008-05-09 2014-01-31 Ｉｇｆ−ｉｉ／ｉｇｆ−ｉｉｅ結合タンパク質

Publications (3)

Publication Number Publication Date
JP2011523405A JP2011523405A (ja) 2011-08-11
JP2011523405A5 JP2011523405A5 (OSRAM) 2013-04-11
JP5734180B2 true JP5734180B2 (ja) 2015-06-17

Family

ID=41265434

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011508703A Expired - Fee Related JP5734180B2 (ja) 2008-05-09 2009-05-08 Ｉｇｆ−ｉｉ／ｉｇｆ−ｉｉｅ結合タンパク質
JP2014016462A Pending JP2014077020A (ja) 2008-05-09 2014-01-31 Ｉｇｆ−ｉｉ／ｉｇｆ−ｉｉｅ結合タンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014016462A Pending JP2014077020A (ja) 2008-05-09 2014-01-31 Ｉｇｆ−ｉｉ／ｉｇｆ−ｉｉｅ結合タンパク質

Country Status (6)

Country Link
US (1) US20110165145A1 (OSRAM)
EP (1) EP2296703A4 (OSRAM)
JP (2) JP5734180B2 (OSRAM)
AU (1) AU2009244091B2 (OSRAM)
CA (1) CA2723722A1 (OSRAM)
WO (1) WO2009137758A2 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012505900A (ja) * 2008-10-14 2012-03-08 ダイアクス コーポレーション 全身性強皮症に伴う肺線維症の治療および予防のためのｉｇｆ−ｉｉ／ｉｇｆ−ｉｉｅ結合タンパク質の使用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
EP2376116B1 (en) 2008-12-12 2015-12-09 Boehringer Ingelheim International GmbH Anti-igf antibodies
US9150644B2 (en) 2011-04-12 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
KR101843248B1 (ko) * 2015-03-17 2018-03-29 고려대학교 세종산학협력단 흉선 기질 림프단백질 매개 신호전달을 제어하는 펩타이드 유도체 및 이를 포함하는 알러지 및 천식 질환 예방 및 치료용 약학 조성물
US10469309B1 (en) * 2016-04-28 2019-11-05 Servicenow, Inc. Management of computing system alerts

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2058041A1 (en) * 1990-06-27 1991-12-28 Katsuichi Sakano Anti-igf-ii monoclonal antibody
JP3213359B2 (ja) * 1990-12-21 2001-10-02 第一製薬株式会社 抗ｉｇｆ−ｉｉモノクローナル抗体
US7438911B2 (en) * 2002-04-30 2008-10-21 Kyowa Hakko Kogyo Co., Ltd. Antibody against human insulin-like growth factor
WO2005018671A1 (ja) * 2003-08-21 2005-03-03 Kyowa Hakko Kogyo Co., Ltd. 癌転移阻害剤
WO2005028515A1 (ja) * 2003-09-24 2005-03-31 Kyowa Hakko Kogyo Co., Ltd. ヒトインスリン様成長因子に対する遺伝子組換え抗体
JPWO2005027970A1 (ja) * 2003-09-24 2007-11-15 協和醗酵工業株式会社 癌治療用医薬
US7612179B2 (en) * 2003-11-28 2009-11-03 Astrazeneca Ab antibodies binding to a C-terminal fragment of apoliopoprotein E
AU2005215024B2 (en) * 2004-02-19 2011-07-21 Dyax Corp. Conformation specific antibodies
JP2008515774A (ja) * 2004-08-03 2008-05-15 ダイアックス コーポレイション ｈＫ１結合タンパク質
WO2007022172A1 (en) * 2005-08-17 2007-02-22 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human monoclonal antibodies that specifically bind igf-ii
ATE552853T1 (de) * 2005-12-13 2012-04-15 Medimmune Ltd Proteine die spezifisch insulin-ähnliche wachstumsfaktoren binden, und deren anwendungen
US8071323B2 (en) * 2006-04-07 2011-12-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human monoclonal antibodies that bind human insulin like growth factors and their use
US8178091B2 (en) * 2007-05-21 2012-05-15 University Of Washington Compositions and methods for the treatment of respiratory disorders

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012505900A (ja) * 2008-10-14 2012-03-08 ダイアクス コーポレーション 全身性強皮症に伴う肺線維症の治療および予防のためのｉｇｆ−ｉｉ／ｉｇｆ−ｉｉｅ結合タンパク質の使用

Also Published As

Publication number Publication date
US20110165145A1 (en) 2011-07-07
CA2723722A1 (en) 2009-11-12
EP2296703A4 (en) 2012-09-05
WO2009137758A2 (en) 2009-11-12
WO2009137758A3 (en) 2010-03-18
AU2009244091A1 (en) 2009-11-12
JP2014077020A (ja) 2014-05-01
AU2009244091B2 (en) 2014-11-27
EP2296703A2 (en) 2011-03-23
JP2011523405A (ja) 2011-08-11

Similar Documents

Publication Publication Date Title
US20230406941A1 (en) Anti-AXL Antagonistic Antibodies
JP5898649B2 (ja) マトリックスメタロプロテイナーゼ結合タンパク質
JP6787796B2 (ja) 抗Ａｘｌ抗体
JP6787795B2 (ja) 抗Ａｘｌ抗体
AU2009303453B2 (en) Use of IGF-II/IGF-IIE binding for the treatment and prevention of systemic sclerosis associated pulmonary fibrosis
JP7825633B2 (ja) ガレクチン－３に対する抗体及びその使用方法
JP2011523414A (ja) 抗ｆｎ１４抗体、およびその使用
TW202525862A (zh) 對cd70具特異性抗體及其用途
JP2014077020A (ja) Ｉｇｆ−ｉｉ／ｉｇｆ−ｉｉｅ結合タンパク質
KR20150036603A (ko) Rspo3 결합제 및 그의 용도
JP2024119840A (ja) ガレクチン－３に対する抗体及びその使用方法
JP2008532476A (ja) 複合結合タンパク質
US10314909B2 (en) Combination therapy comprising an MMP-14 binding protein
US20220195037A1 (en) Compositions and methods for inhibiting cancer stem cells
HK40096197A (zh) 抗axl拮抗抗体
HK1123740B (en) Metalloproteinase binding proteins

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120312

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131031

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140131

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140828

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20141224

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150122

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150318

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150414

R150 Certificate of patent or registration of utility model

Ref document number: 5734180

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees